[1]王恒,邱婷婷,徐开林*.异基因造血干细胞移植后继发性血小板减少患者的危险因素及预后意义分析[J].徐州医科大学学报,2022,42(03):170-174.[doi:10.3969/j.issn.2096-3882.2022.03.003]

点击复制

异基因造血干细胞移植后继发性血小板减少患者的危险因素及预后意义分析()

分享到：

《徐州医科大学学报》[ISSN:2096-3882/CN:32-1875/R]

Title:: Analysis of clinical characteristics of patients with secondary thrombocytopenia after allogeneic hematopoietic stem cell transplantation

摘要:: 目的：探讨异基因造血干细胞移植(allo-HSCT)后继发性血小板减少的危险因素及其预后意义。方法：回顾性分析2013年1月至2020年6月在徐州医科大学附属医院接受allo-HSCT的264例患者的临床资料。根据患者移植后+60d血小板水平，分为血小板减少组和对照组，分析血小板减少的危险因素及预后意义。结果：血小板减少组与对照组相比，CMV感染率显著增高（P=0.002)。多因素分析显示CMV感染为继发性血小板减少的独立危险因素。血小板减少组1年及3年OS率与DFS率均显著低于对照组（P<0.001），血小板减少组1年及3年非复发死亡率（NRM）均高于对照组。多因素分析显示+60d PLT<30×109/L是影响OS率、DFS率及NRM的独立危险因素（P<0.001）。结论：CMV感染与移植后继发性血小板减少相关，发生继发性血小板减少的患者预后不良。

Abstract:: ob＜x＞jective: To investigate the risk factors and prognostic significance of secondary thrombocytopenia after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: The clinical data of 264 patients who received allo-HSCT in the affiliated Hospital of Xuzhou Medical University from January 2013 to June 2020 were retrospectively analyzed. According to the platelet level of +60d after transplantation, the patients were divided into thrombocytopenia group and control group. The risk factors and prognostic significance of thrombocytopenia were analyzed. Results: The infection rate of CMV in the thrombocytopenia group was significantly higher than that in the control group (P =0.002). Multivariate analysis showed that CMV infection was an independent risk factor for secondary thrombocytopenia. The 1-year and 3-year overall survival (OS) rate and disease-free survival (DFS) rate in the thrombocytopenia group was lower than that in the control group (P<0.001). The 1-year and 3-year non-relapse mortality in the thrombocytopenia group was higher than that in the control group. Multivariate analysis showed that +60d PLT<30×109/L was an independent risk factor affecting OS rate, DFS rate and NRM(P<0.001). Conclusion: CMV infection is associated with secondary thrombocytopenia after allo-HSCT, and the prognosis of patients with secondary thrombocytopenia is poor

[1]主鸿鹄.移植物抗白血病和移植物抗宿主病的可分离性及分离策略[J].徐州医科大学学报,2002,22(03):278.
　[J].Journal of Xuzhou Medical University,2002,22(03):278.
[2]傅荣.自体造血干细胞移植治疗进展型多发性硬化的护理[J].徐州医科大学学报,2003,23(05):461.
　[J].Journal of Xuzhou Medical University,2003,23(03):461.
[3]孙海英、李振宇、徐开林等.造血干细胞移植后巨细胞病毒感染临床分析[J].徐州医科大学学报,2006,26(06):543.
　[J].Journal of Xuzhou Medical University,2006,26(03):543.
[4]赵玉凤、冯媛媛、何莉丽、张蓓、韩雪、袁久莲、马慧杰、孙金凤.1例异体造血干细胞移植并发重症肝炎的护理体会[J].徐州医科大学学报,2014,34(01):65.
　[J].Journal of Xuzhou Medical University,2014,34(03):65.

更新日期/Last Update: 2022-05-09